A Review on Measures to Rejuvenate Immune System: Natural Mode of Protection Against Coronavirus Infection

Islam, Md. Aminul; Haque, Atiqul; Rahman, Md. Arifur; Hossen, Foysal; Reza, Mahin; Barua, Abanti; Marzan, Abdullah Al; Das, Tuhin; Baral, Sumit; He, Cheng; Ahmed, Firoz; Bhattacharya, Prosun; Jakariya, Md.

doi:10.3389/fimmu.2022.837290

Cited by 34 publications

(24 citation statements)

References 235 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We then manually searched PubMed for articles within our 598 that were related to Covid-19, and found 15 relevant papers (Table 4). Six of them are reviews [37][38][39][40][41][42], two studies provide perhaps the clearest evidence on the subject [43,44]; one is a comparative study that perhaps provides the clearest evidence on the subject [44]. It is a retrospective report on 311 patients with severe Covid-19, treated in February of 2020 at the Wuhan Union Hospital, China.…”

Section: Nutraceuticals and Covid-19 (Sars-cov-2)mentioning

confidence: 99%

Nutraceuticals in Personalized and Precision Medicine – a preliminary scoping review indicates efficacy for disease treatment, general wellbeing, and defense against Covid-19

Zahir¹

2022

Preprint

View full text Add to dashboard Cite

Nutraceuticals have taken the spotlight during the past two decades as evidenced by the exponential publications on them. Long a part of routine in Traditional Medicine Systems, the rise of their mainstream use globally raises both safety concerns and need for better understanding of efficacious dosing. We attempt to answer these questions in this preliminary scoping review by an analysis of current literature on nutraceutical use as a personalized or prescription medicine. Using Covidence, Rayyan, and manual searches of PubMed, 598 unique publications were selected. 32 are systematic reviews, of which we overview the scope. We also overview 30 papers that address adverse drug reactions. To obtain an unbiased landscape of the 598 papers, we analyzed keywords using multiple methods. Expectedly, the most frequent keywords were probiotics and vitamins. Unexpectedly and remarkably, among the highest keyword yield was ‘COVID’. Further exploring this aspect, we review 15 pertinent papers, that not only provide robust evidence for nutraceutical benefits as part of SARS-CoV-2 treatment, but also amplify the notion that nutraceuticals are protective. Overall, the strident note is that further robust targeted research is needed in order to reap the full benefits of nutraceuticals in a safe and efficacious manner.

show abstract

Section: Nutraceuticals and Covid-19 (Sars-cov-2)mentioning

confidence: 99%

Nutraceuticals in Personalized and Precision Medicine – a preliminary scoping review indicates efficacy for disease treatment, general wellbeing, and defense against Covid-19

Zahir¹

2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Although the COVID-19 public health emergency status on cessation, the world is challenged by another new reemerging outbreak of the Monkeypox disease (MPXD). Although there is extensive literature on the ongoing pandemic (COVID-19) caused by the zoonotic SARS-CoV-2 virus [ 1 , 2 , 3 , 4 ], very little is known about the Monkeypox (MPX) outbreak––which has already infected 65,353 people, with 20 death cases in 111 countries (as of 9 November 2022). The top three countries with the highest MPXD cases include the US (26,385), Brazil (7300), and Spain (7083) (WHO, 2022) [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Association between Global Monkeypox Cases and Meteorological Factors

Islam

Sangkham

Tiwari

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

The emergence of an outbreak of Monkeypox disease (MPXD) is caused by a contagious zoonotic Monkeypox virus (MPXV) that has spread globally. Yet, there is no study investigating the effect of climatic changes on MPXV transmission. Thus, studies on the changing epidemiology, evolving nature of the virus, and ecological niche are highly paramount. Determination of the role of potential meteorological drivers including temperature, precipitation, relative humidity, dew point, wind speed, and surface pressure is beneficial to understand the MPXD outbreak. This study examines the changes in MPXV cases over time while assessing the meteorological characteristics that could impact these disparities from the onset of the global outbreak. To conduct this data-based research, several well-accepted statistical techniques including Simple Exponential Smoothing (SES), Auto-Regressive Integrated Moving Average (ARIMA), Automatic forecasting time-series model (Prophet), and Autoregressive Integrated Moving Average with Explanatory Variables (ARIMAX) were applied to delineate the correlation of the meteorological factors on global daily Monkeypox cases. Data on MPXV cases including affected countries spanning from May 6, 2022, to November 9, 2022, from global databases and meteorological data were used to evaluate the developed models. According to the ARIMAX model, the results showed that temperature, relative humidity, and surface pressure have a positive impact [(51.56, 95% confidence interval (CI): −274.55 to 377.68), (17.32, 95% CI: −83.71 to 118.35) and (23.42, 95% CI: −9.90 to 56.75), respectively] on MPXV cases. In addition, dew/frost point, precipitation, and wind speed show a significant negative impact on MPXD cases. The Prophet model showed a significant correlation with rising MPXD cases, although the trend predicts peak values while the overall trend increases. This underscores the importance of immediate and appropriate preventive measures (timely preparedness and proactive control strategies) with utmost priority against MPXD including awareness-raising programs, the discovery, and formulation of effective vaccine candidate(s), prophylaxis and therapeutic regimes, and management strategies.

show abstract

“…[1][2][3] The most devastative coronavirus disease 2019 (COVID-19) pandemic disease has attacked the world economy, where people lost about 6.6 million lives including 640 million total positive cases as of December 5, 2022. [3][4][5][6][7] The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has drawn high public health attention against zoonotic infections, 3 and novel, emerging or reemerging pathogens, to develop new vaccines and therapeutic regimens but recently during this 2022 year another zoonotic viral disease, namely Monkeypox (MPX) caused by Monkeypox virus (MPXV), has also re-emerged in multiple countries with its cases increasing day after day without control that paused global public health emergency of international emergency. [8][9][10][11] MPXV is an enveloped DNA virus under the Poxviridae family and genus Orthopox virus.…”

Section: Introductionmentioning

confidence: 99%

Old Enemy with a New Face: Re-emerging Monkeypox Disease – An Update

Islam¹,

Hemo²,

Chopra³

et al. 2022

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

Human monkeypox (MPX), a multi-country re-emerging disease, is rapidly spreading around the world. The etiological agent of this disease, Monkeypox virus (MPXV), is a DNA virus classified into three genetic types (West Africa, Congo Basin clade, and one new clade-3). Atypical or unusual symptoms as well as asymptomatic infection of MPXV has also been reported. Transmission among humans is possible by droplets, contact, sexual intercourse, and fomites. Secondary transmission of this disease has been reported to occur in less than 10% of cases where it was found 35%–88% of smallpox. Mother-to-fetus transmission by vertical route is also possible for this disease. Modern equipment, biosafety level-3 laboratory facilities, and trained expert persons are needed to diagnose this disease. Previous data support that ~85% clinical protection is provided by smallpox vaccines for monkeypox, although initially non-human primates models were used for various experiments, and also side-effects of this vaccine have been notably mentioned in various studies. Limited research findings of JYNNEOS vaccine has supported the comparatively lower prevalence of MPX cases with vaccination. Few drugs, including cidofovir, tecovirimat, brincidofovir, and vaccinia immune globulin intravenous are preferable against this disease, although clinical trial data is limited and FDA-approval is also pending. This review-based study presents an overall scenario of Monkeypox disease (MPXD) based on previously published studies. Recommended clinical treatment and vaccination, appropriate infection prevention and control strategies, adopting one health approach, and quick identification of hotspots using a wastewater-based surveillance system need to be followed to check the further spread of MPX outbreaks.

show abstract

A Review on Measures to Rejuvenate Immune System: Natural Mode of Protection Against Coronavirus Infection

Cited by 34 publications

References 235 publications

Nutraceuticals in Personalized and Precision Medicine – a preliminary scoping review indicates efficacy for disease treatment, general wellbeing, and defense against Covid-19

Nutraceuticals in Personalized and Precision Medicine – a preliminary scoping review indicates efficacy for disease treatment, general wellbeing, and defense against Covid-19

Association between Global Monkeypox Cases and Meteorological Factors

Old Enemy with a New Face: Re-emerging Monkeypox Disease – An Update

Contact Info

Product

Resources

About